Medtronic (MDT) Could Be 24% Undervalued As CPT Code Wins Support Growth
Medtronic (MDT) received permanent CPT codes for its Altaviva and Symplicity Spyral devices. Shares are down 7.52% in 1 month and 9.33% YTD, but up 26.12% over 3 years. Analysts estimate MDT is 24.5% undervalued with a fair value of $115.38 vs. last close at $87.09. Management hinted at higher growth aspirations, to be detailed in December.
How this was made
The 30-second read
Why it matters
The regulatory win is presented as a catalyst that could narrow the perceived undervaluation.
Market read
Regulatory approval for key products may drive short‑term buying interest in MDT.
What to watch
Potential competition from alternative renal denervation technologies could temper growth
Background
The article is a Simply Wall St commentary highlighting Medtronic's recent CPT code approvals and valuation gap.
Ticker impact
Medtronic received permanent Category I CPT code approvals for its Altaviva neuromodulation implant and Symplicity Spyral renal denervation system, a regulatory win that could improve reimbursement and sales.
likely upward pressure as investors price in improved reimbursement prospects
CPT code acceptance removes billing uncertainty, a material catalyst for revenue growth in the device segments.
Market effects
May lift other med‑device firms awaiting similar CPT approvals
U.S. healthcare sector could see modest gains
Limited to U.S. market but could influence global med‑device valuations
Counterpoint
If reimbursement rates are lower than expected, the approval may not translate into revenue upside
Key entities
- companyMedtronic
Medical device manufacturer listed on NYSE (MDT)
